Multiple Myeloma Clinical Trials

Multiple myeloma clinical trials provide patients with exciting opportunities to be among the first to receive and benefit from promising new treatments before those options are widely available in other settings. In doing so, participants also help to accelerate the development of next-generation treatments that will benefit all current and future cancer patients.

The purpose of a clinical trial is to assess the effectiveness of a new treatment in comparison to that of existing treatments. Prior to being used a clinical trial, a new treatment is tested extensively to confirm its safety. Many people assume that placebos are used in cancer clinical trials, but that is not the case. Instead, a participant can expect to receive either a brand-new treatment or the current “best standard” treatment that is currently available.

At Moffitt Cancer Center, we perform extensive research and have an active multiple myeloma clinical trials program. Our scientists and clinicians are currently evaluating:

  • Drug therapies to control myeloma or alleviate symptoms
  • Stem cell transplants used in combination with high-dose chemotherapy
  • Biphosphonates for treating bone complications that often accompany multiple myeloma
  • Radiation therapy to destroy the cancer cells or inhibit their growth
  • Surgical techniques designed to repair fractures, manage pain and improve function and mobility

As the only National Cancer Institute-designated Comprehensive Cancer Center based in Florida, Moffitt continues to lead the way in cancer research. Our multiple myeloma clinical trials are transforming the treatment landscape by eliminating obstacles and speeding up every step of the drug research and development process. These important research studies are the most reliable scientific method for determining whether a new treatment works better than the current standard of care.

To learn more about the multiple myeloma clinical trials currently underway at Moffitt,  call 1-813-745-6100 or 1-800-679-0775 (toll-free) or submit a clinical trials inquiry form online. We can help you determine whether you qualify for one of our trials, and we do not require referrals. 

calledFromCancerPage=True - substr=
testProtocol=

Open Clinical Trials:

Showing of 50

CLINICAL TRIAL 19428

A Phase 1/2, Multicenter, Dose-Escalation and Expansion Study of Combination Therapy with Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Subjects with Relapsed or Refractory Multiple Myeloma

Disease Site: Multiple Myeloma

View Trial Details

CLINICAL TRIAL 19722

A Phase 2, Multi-Cohort, Open-Label, Multicenter Study To Determine The Efficacy And Safety Of Bb2121 In Subjects With Relapsed And Refractory Multiple Myeloma And In Subjects With High-Risk Multiple Myeloma Having Progressed Within One Year Of Initial Treatment

Disease Site: Multiple Myeloma

View Trial Details

CLINICAL TRIAL 20038

Phase I Dose-Escalation and Dose-Expansion Trial of a Novel Glutaminase Inhibitor (CB-839 HCl) in Combination with Carfilzomib and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma

Disease Site: Multiple Myeloma

View Trial Details

CLINICAL TRIAL 20130

Phase II Study of Daratumumab Based Response Adapted Therapy for Older Adults with Newly Diagnosed Multiple Myeloma

Disease Site: Multiple Myeloma

View Trial Details

CLINICAL TRIAL 20253

Open Label, Multi-Center, Phase 1b Clinical Trial to Evaluate the Safety and Efficacy of Autologous CAR-BCMA T cells (CT053) in Patients With Relapsed and/or Refractory Multiple Myeloma

Disease Site: Multiple Myeloma

View Trial Details

CLINICAL TRIAL 20361

A Phase 1, Open-Label, Multi-Center, Dose Escalation and Dose Expansion Study of NKTR-255 As A Single Agent In Relapsed Or Refractory Hematological Malignancies and In Combination With Daratumumab As A Salvage Regimen for Multiple Myeloma

Disease Site: Multiple Myeloma

View Trial Details

CLINICAL TRIAL 20615

A Phase 1 Open-Label, Multi-Center First in Human Study of TnMUC1-Targeted Genetically-Modified Chimeric Antigen Receptor T Cells in Patients with Advanced TnMUC1-Positive Solid Tumors and Multiple Myeloma

Disease Site: Breast, Lung, Multiple Myeloma, Ovary, Pancreas

View Trial Details

CLINICAL TRIAL 20753

An Open-Label Phase I, Multi-Center Study to Determine the Recommended Dose of the Chimeric Antigen Receptor T-cell Treatment CYAD-211 After a Non-Myeloablative Preconditioning Chemotherapy in Multiple Myeloma Patients with Relapsed or Refractory Disease (IMMUNICY-1)

Disease Site: Multiple Myeloma

View Trial Details

CLINICAL TRIAL 21249

A Phase 2, Open-Label, Multi-Center Study of Venetoclax in Combination with Carfilzomib and Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma

Disease Site: Multiple Myeloma

View Trial Details

CLINICAL TRIAL 20413

Phase III Study Of Daratumumab/Rhuph20 (Nsc- 810307) + Lenalidomide Or Lenalidomide As Post-Autologous Stem Cell Transplant Maintenance Therapy In Patients With Multiple Myeloma (MM) Using Minimal Residual Disease To Direct Therapy Duration (DRAMMATIC STUDY)

Disease Site: Multiple Myeloma

View Trial Details

CLINICAL TRIAL 18926

The National Myelodysplastic Syndromes (MDS) Study

Disease Site: Leukemia, other, Lymphoid Leukemia, Multiple Myeloma, Myeloid and Monocytic Leukemia

View Trial Details

CLINICAL TRIAL 20156

Mindfulness in AYA Patients Undergoing Hematopoietic Stem Cell Transplantation: A Pilot Proposal

Disease Site: Multiple Myeloma, Unknown Sites, Leukemia, other

View Trial Details

CLINICAL TRIAL 21219

Predicting Progression of Developing Myeloma in a High-Risk Screened Population

Disease Site: Multiple Myeloma

View Trial Details